A multi-centre, double-blind, randomised-withdrawal, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine SR [sustained-release] as monotherapy in the maintenance treatment of patients with GAD [generalised anxiety disorder] following an open-label stabilisation period

Trial Profile

A multi-centre, double-blind, randomised-withdrawal, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine SR [sustained-release] as monotherapy in the maintenance treatment of patients with GAD [generalised anxiety disorder] following an open-label stabilisation period

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2013

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Generalised anxiety disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms PLATINUM
  • Sponsors AstraZeneca
  • Most Recent Events

    • 22 May 2010 Functioning and sleep quality results reported at the 163rd Annual Meeting of the American Psychiatric Association.
    • 19 May 2009 Results presented at the 162nd Annual Meeting of the American Psychiatric Association (APA 2009).
    • 01 Apr 2009 Actual end date changed from Oct 2007 to Aug 2007 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top